Minerva Neurosciences, Inc.NERVNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+57.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+57.2%/yr
vs +26.3%/yr prior
Acceleration
+30.9pp
Accelerating
Percentile
P95
Near historical high
vs 3Y Ago
3.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 134.93% |
| Q3 2025 | -28.71% |
| Q2 2025 | -4.73% |
| Q1 2025 | -31.29% |
| Q4 2024 | 5.03% |
| Q3 2024 | -51.10% |
| Q2 2024 | -7.36% |
| Q1 2024 | -11.72% |
| Q4 2023 | 37.09% |
| Q3 2023 | 82.44% |
| Q2 2023 | -28.87% |
| Q1 2023 | -16.81% |
| Q4 2022 | 34.74% |
| Q3 2022 | -42.71% |
| Q2 2022 | -16.69% |
| Q1 2022 | -73.54% |
| Q4 2021 | 315.39% |
| Q3 2021 | -18.26% |
| Q2 2021 | 69.42% |
| Q1 2021 | -8.24% |
| Q4 2020 | -23.44% |
| Q3 2020 | -19.57% |
| Q2 2020 | -28.65% |
| Q1 2020 | -71.66% |
| Q4 2019 | 194.85% |
| Q3 2019 | 16.27% |
| Q2 2019 | -28.31% |
| Q1 2019 | 28.84% |
| Q4 2018 | 7.64% |
| Q3 2018 | -7.65% |
| Q2 2018 | 7.26% |
| Q1 2018 | 29.17% |
| Q4 2017 | -26.97% |
| Q3 2017 | 25.36% |
| Q2 2017 | -6.17% |
| Q1 2017 | 17.16% |
| Q4 2016 | 11.06% |
| Q3 2016 | 115.62% |
| Q2 2016 | -49.51% |
| Q1 2016 | -14.12% |